NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)

NCT05103358
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TSC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases: 
Additional Notes: Patients must have tumors that express a TSC1 or TSC2 alteration
Exclusions: Patients with prior treatment of an mTOR inhibitor, including nab-sirolimus; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05103358

Comments are closed.

Up ↑